Trichostatin A
- Generic Name
- Trichostatin A
- Drug Type
- Small Molecule
- Chemical Formula
- C17H22N2O3
- CAS Number
- 58880-19-6
- Unique Ingredient Identifier
- 3X2S926L3Z
Vanda Pharmaceuticals Reports Revenue Increase and Advances Pipeline in Q3 2024
• Vanda Pharmaceuticals reported a 23% increase in Q3 2024 revenues, reaching $47.7 million, driven by sales of Fanapt, HETLIOZ, and PONVORY.
• The company is advancing its psychiatry portfolio, with plans to submit an NDA for milsaperidone for schizophrenia and bipolar I disorder in early 2025.
• Vanda initiated the commercial launch of PONVORY for multiple sclerosis and is exploring its use in psoriasis and ulcerative colitis with IND submissions expected in Q4 2024.
• A New Drug Application for tradipitant in motion sickness is expected to be submitted in Q4 2024, building on positive clinical trial results.
HDAC Inhibition in Muscle Cells Enhances Bone Regeneration via Extracellular Vesicles
• Histone deacetylase (HDAC) inhibition using Trichostatin A (TSA) in human skeletal muscle myoblasts (HSMMs) promotes myotube formation and myogenic gene expression.
• Extracellular vesicles (EVs) from TSA-treated HSMMs (TSA-EVs) exhibit enhanced properties and prevent ovariectomized-induced bone loss in mice, increasing bone mineral density.
• TSA-EVs promote osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) and inhibit osteoclast formation, highlighting their potential for bone regeneration.
• TSA treatment mimics exercise effects on bone formation by upregulating miR-873-3p in EVs, which targets CNN2 to promote osteogenesis in hBMSCs.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath